Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7707 USD | -0.75% |
|
-9.33% | -86.83% |
06-04 | Augmedix, Inc. Reiterates Earnings Guidance for the Second Quarter and Full Year of 2024 | CI |
05-29 | Augmedix Appoints Alex Stinard as Chief Clinical AI Officer | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 117 | 58.39 | 284 | 37.74 | - | - |
Enterprise Value (EV) 1 | 90.3 | 58.39 | 284 | 32.78 | 37.74 | 37.74 |
P/E ratio | -5.08 x | -2.39 x | -13.3 x | -1.41 x | -1.62 x | - |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 5.28 x | 1.89 x | 6.33 x | 0.71 x | 0.57 x | 0.61 x |
EV / Revenue | 4.07 x | 1.89 x | 6.33 x | 0.62 x | 0.57 x | 0.61 x |
EV / EBITDA | -5.88 x | -3.14 x | -18.7 x | -1.45 x | -2.13 x | -3 x |
EV / FCF | -4.7 x | -3.21 x | - | -1.77 x | -3.85 x | 15.1 x |
FCF Yield | -21.3% | -31.1% | - | -56.4% | -26% | 6.62% |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 37,158 | 37,432 | 48,555 | 48,968 | - | - |
Reference price 2 | 3.150 | 1.560 | 5.850 | 0.7707 | 0.7707 | 0.7707 |
Announcement Date | 22-03-21 | 23-03-27 | 24-03-18 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | 22.16 | 30.93 | 44.86 | 53.2 | 66.58 | 62 |
EBITDA 1 | - | - | -15.35 | -18.59 | -15.21 | -22.67 | -17.76 | -12.6 |
EBIT 1 | - | - | -17.94 | -22.37 | -18.78 | -26.83 | -22.47 | - |
Operating Margin | - | - | -80.93% | -72.32% | -41.87% | -50.43% | -33.75% | - |
Earnings before Tax (EBT) 1 | - | - | -17.85 | -24.45 | -19.03 | -29.1 | -25.66 | - |
Net income 1 | -18.5 | -15.6 | -17.85 | -24.45 | -19.17 | -29.08 | -25.72 | - |
Net margin | - | - | -80.54% | -79.04% | -42.74% | -54.66% | -38.63% | - |
EPS 2 | -9.360 | -2.220 | -0.6200 | -0.6534 | -0.4400 | -0.5475 | -0.4767 | - |
Free Cash Flow 1 | - | - | -19.2 | -18.18 | - | -18.5 | -9.8 | 2.5 |
FCF margin | - | - | -86.64% | -58.78% | - | -34.77% | -14.72% | 4.03% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 21-02-08 | 21-03-31 | 22-03-21 | 23-03-27 | 24-03-18 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 6.577 | 6.985 | 7.333 | 7.864 | 8.751 | 9.628 | 10.78 | 11.77 | 12.68 | 13.47 | 13.65 | 12.96 | 13.19 | 15.07 | 16.28 |
EBITDA 1 | -3.838 | -4.688 | -5.257 | -4.52 | -4.178 | -4.148 | -3.597 | -3.079 | -3.306 | -5.078 | -5.627 | -6.089 | -5.922 | -5.206 | -4.618 |
EBIT 1 | -4.827 | -5.445 | -6.051 | -5.458 | -5.44 | -5.094 | -4.934 | -4.403 | -4.347 | -6.402 | -6.614 | -7.054 | -6.939 | -6.777 | -6.045 |
Operating Margin | -73.39% | -77.95% | -82.52% | -69.4% | -62.16% | -52.91% | -45.77% | -37.42% | -34.28% | -47.52% | -48.47% | -54.43% | -52.6% | -44.95% | -37.13% |
Earnings before Tax (EBT) 1 | -5.451 | -5.936 | -7.447 | -5.49 | -5.599 | -5.239 | -5.033 | -4.407 | -4.515 | -6.579 | -7.151 | -7.746 | -7.62 | -7.209 | -6.502 |
Net income 1 | -5.451 | -5.936 | -7.447 | -5.49 | -5.599 | -5.239 | -5.033 | -4.407 | -4.491 | -6.499 | -7.161 | -7.757 | -7.632 | -7.226 | -6.522 |
Net margin | -82.88% | -84.98% | -101.55% | -69.81% | -63.98% | -54.41% | -46.69% | -37.45% | -35.42% | -48.24% | -52.47% | -59.86% | -57.85% | -47.94% | -40.06% |
EPS 2 | -0.1600 | -0.1600 | -0.2000 | -0.1500 | -0.1453 | -0.1397 | -0.1200 | -0.1000 | -0.0900 | -0.1200 | -0.1350 | -0.1450 | -0.1450 | -0.1350 | -0.1200 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 22-03-21 | 22-05-09 | 22-08-08 | 22-11-14 | 23-03-27 | 23-05-15 | 23-08-07 | 23-11-06 | 24-03-18 | 24-05-13 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - | - |
Net Cash position 1 | - | - | 26.8 | - | - | 4.96 | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | -19.2 | -18.2 | - | -18.5 | -9.8 | 2.5 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | 0.61 | 1.41 | - | - | - | - |
Capex / Sales | - | - | 2.76% | 4.55% | - | - | - | - |
Announcement Date | 21-02-08 | 21-03-31 | 22-03-21 | 23-03-27 | 24-03-18 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-86.83% | 37.74M | |
+17.39% | 71.78B | |
+8.43% | 17.62B | |
+20.23% | 14.7B | |
+17.62% | 12.84B | |
+12.44% | 9.64B | |
-10.29% | 5.6B | |
+3.95% | 5.3B | |
+9.65% | 4.89B | |
-5.09% | 4.76B |
- Stock Market
- Equities
- AUGX Stock
- Financials Augmedix, Inc.